S044 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
An evidence-based approach for the use of medical therapies for HS, including topical agents, antibiotics, non-antibiotic systemics, biologics, small molecule inhibitors, pain management and wound care, will be discussed. This session will review hidradenitis suppurativa (HS) epidemiology and comorbidities, and discuss comorbidity screening. An evidence-based approach for the use of surgical therapies for HS, including office-based procedures, will be reviewed. The patient perspective of living with HS and approaches to ensuring therapeutic access will also be discussed.
LEARNING OBJECTIVES
Apply appropriate medical, procedural, pain management and wound care strategies for hidradenitis suppurativa.
Describe hidradenitis suppurativa epidemiology and comorbidities, and initiate comorbidity screening.
Recognize the patient experience of living with hidradenitis suppurativa and apply effective strategies to increase treatment access for people with HS.
SCHEDULE
5:00 PM
Introduction
Haley Naik, MD, FAAD
5:10 PM
HS Medical Management with Novel Biologics and Small Molecule Inhibitors
Haley Naik, MD, FAAD
5:30 PM
HS Medical Management with Nonbiologic Therapies
Christopher John Sayed, MD, FAAD
5:50 PM
Overcoming Barriers to HS Therapeutic Access
Tiffany Mayo, MD, FAAD
6:10 PM
Moderated Q&A
6:25 PM
Comorbidity Screening in HS
Ra'ed Alhusayen, MD, MSc, FAAD
6:45 PM
Pain Management Considerations for HS
Lauren Orenstein, MD, FAAD
7:05 PM
Wound Care Considerations for HS
Hadar Lev-Tov, MD, FAAD
7:25 PM
Office-based Surgical Procedures for HS
Drew Kenith Saylor, MD, FAAD
7:45 PM
Moderated Q&A
SPEAKERS
Ra'ed Alhusayen, MD, MSc, FAAD
Hadar Lev-Tov, MD, FAAD
Tiffany Mayo, MD, FAAD
Haley Naik, MD, FAAD
Lauren Orenstein, MD, FAAD
Christopher John Sayed, MD, FAAD
Drew Kenith Saylor, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Ra'ed Alhusayen, MD, MSc, FAAD
AbbVie – Advisory Board(Honoraria), Speaker(Honoraria); Bausch Health – Investigator(Fees), Investigator(Grants/Research Funding); Canadian Dermatology Association – Board of Directors(No Compensation Received); Canadian Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received); Fresenius Kabi – Advisory Board(Honoraria); Incyte – Investigator(Fees), Investigator(Grants/Research Funding); janssen – Advisory Board(Honoraria), Investigator(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria), Speaker/Faculty Education(Honoraria); Pfizer Inc. – Advisory Board(Honoraria); Sandoz Pharmaceuticals AG – Advisory Board(Honoraria); Sun Pharma Advanced Research Company (SPARC) – Advisory Board(Honoraria); UCB Pharma – Advisory Board(Honoraria);
Hadar Lev-Tov, MD, FAAD
AbbVie – Consultant(Fees); BSN Medical – Investigator(Grants/Research Funding), Speaker(Honoraria); Cosmo Pharmaceuticals Inc. – Consultant (1099 relationship)(Fees); Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received); HidraMed Solutions – Advisory Board(Fees); Incyte Corporation – Investigator(No Compensation Received); Insmed Incorporated – Consultant (1099 relationship)(Fees); LearnHealth/LearnSkin – Founder(Stock); Learnskin – Founder(Stock Options); Medline Industries, Inc. – Investigator(Grants/Research Funding), Speaker(Honoraria); Molynlycke – Consultant(Fees), Speaker(Honoraria); Next Science – Consultant(Fees); Novartis – Consultant(Fees); Pfizer Inc. – Advisory Board(Honoraria), Consultant(Fees), Investigator(No Compensation Received); SAWC – Speaker(Honoraria); TissueTech – Investigator(No Compensation Received); UCB – Investigator(No Compensation Received); Vomaris Innovations Inc – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding);
Tiffany Mayo, MD, FAAD
AbbVie – Consultant (1099 relationship)(Honoraria); Acelyrin – Investigator(Grants/Research Funding); Arcutis Biotherapeutics – Advisory Board(Honoraria); Bristol-Myers Squibb – Advisory Board(Honoraria), Investigator(Grants/Research Funding); ChemoCentryx – Investigator(Grants/Research Funding); Eli Lilly and Company – Investigator(Grants/Research Funding); Galderma – Investigator(Grants/Research Funding); Incyte – Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Merck – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Procter & Gamble Company – Investigator(Grants/Research Funding); Sanofi – Advisory Board(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); UCB – Advisory Board(Honoraria);
Haley Naik, MD, FAAD
23andMe – Consultant(Honoraria); AbbVie – Consultant(Honoraria), Other(Grants/Research Funding); Aristea Therapeutics, Inc. – Consultant(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria); Dava Oncology – Consultant(Honoraria); Johnson and Johnson – Consultant(Honoraria); Medscape – Consultant (1099 relationship)(Fees); Nimbus Therapeutics – Consultant(Honoraria); Novartis – Consultant (1099 relationship)(Fees); Radera Biotherapeutics, Inc. – Stockholder Private Company(Stock Options); Radera, Inc. – Stockholder Private Company(Stock Options); Sonoma Biotherapeutics – Consultant (1099 relationship)(Fees); UCB – Consultant (1099 relationship)(Fees);
Lauren Orenstein, MD, FAAD
HS Foundation – Board of Directors(No Compensation Received); Incyte Corporation – Advisory Board(Fees); Novartis – Advisory Board(Fees), Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); Phrase Health – Stockholder(Stock); UCB Pharma – Advisory Board(Fees);
Christopher John Sayed, MD, FAAD
AbbVie – Advisory Board(Fees), Investigator(Fees), Speaker(Fees); Alumis – Consultant(Fees); AstraZeneca – Consultant (1099 relationship)(Fees); ChemoCentryx – Investigator(Grants/Research Funding); Elasmogen – Consultant (1099 relationship)(Fees); Eli Lilly – Stockholder Public Company(Stock); Incyte – Consultant (1099 relationship)(Fees); Incyte Corporation – Investigator(Grants/Research Funding); InflaRx – Consultant(Fees), Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Investigator(Fees), Speaker(Honoraria); Sandoz Pharmaceuticals AG – Consultant (1099 relationship)(Honoraria); Sanofi – Consultant (1099 relationship)(Fees); UCB – Advisory Board(Honoraria), Consultant(Fees), Investigator(Grants/Research Funding);
Drew Kenith Saylor, MD, FAAD
No financial relationships exist with ineligible companies.